The new Dogma meets Thomas Kuhn’s definition of a paradigm shift. The DNA/RNA Dogma is sufficiently unprecedented to attract ...

A study led by the University of Barcelona and the Spanish National Research Council's Institute for Advanced Chemistry of ...

The assessment considered forecasts of power demand, planned upgrades to the transmission system, public policy and changes ...

“The conclusion is convincing that there was infection in the animals,” says Spyros Lytras, an evolutionary virologist at the ...

Researchers find that SARS-CoV-2 spike protein persists in the skull-meninges-brain axis, driving neuroinflammation, ...

Debilitating chronic fatigue syndrome creates conditions where a kind of immune cell that identifies and kills pathogens, ...

H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...

Alan Herbert, President of InsideOutBio, guides us through targeting the most complex flipon of them all in the fight against ...

Cape Cod Healthcare will participate in a new national clinical research study focused on early detection of lung cancer with ...

The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to ...

Arrowhead (ARWR) announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the ...

A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the fatal illness. Huntington’s is an inherited condition that is caused by a ...